{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:27:14Z","timestamp":1784618834306,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12350-018-1307-7","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T12:59:34Z","timestamp":1527685174000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis"],"prefix":"10.1016","volume":"27","author":[{"given":"Andrew J.","family":"Einstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Shuryak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiva","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-018-1307-7_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: An update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Clevel Clin J Med"},{"key":"10.1007\/s12350-018-1307-7_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99 m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-018-1307-7_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(77)91102-3","article-title":"Scanning for soft-tissue amyloid","volume":"1","author":"Kula","year":"1977","journal-title":"Lancet"},{"key":"10.1007\/s12350-018-1307-7_bib4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","article-title":"Value of positive myocardial 99mTc-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis","volume":"103","author":"Wizenberg","year":"1982","journal-title":"Am Heart J"},{"key":"10.1007\/s12350-018-1307-7_bib5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0002-9149(83)80140-4","article-title":"Sensitivity of 99mTc-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis","volume":"51","author":"Falk","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-018-1307-7_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/hrt.52.3.321","article-title":"Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and 99mTc-pyrophosphate scintigraphy","volume":"52","author":"Eriksson","year":"1984","journal-title":"Br Heart J"},{"key":"10.1007\/s12350-018-1307-7_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0167-5273(87)90209-9","article-title":"99mTc-pyrophosphate single-photon emission computed tomography of the heart in familial amyloid polyneuropathy","volume":"14","author":"Karp","year":"1987","journal-title":"Int J Cardiol"},{"key":"10.1007\/s12350-018-1307-7_bib8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archinte.1987.00370060035007","article-title":"Utility of 99mTc-pyrophosphate bone scanning in cardiac amyloidosis","volume":"147","author":"Gertz","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1007\/s12350-018-1307-7_bib9","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-1307-7_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s12350-017-1141-3","article-title":"Cardiac ATTR amyloid nuclear imaging\u2014not all bone scintigraphy radionuclide tracers are created equal","author":"Yang","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-018-1307-7_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cardfail.2017.12.006","article-title":"More than meets the eye: Time for a new imaging paradigm to test for cardiac amyloidosis","volume":"24","author":"Maurer","year":"2018","journal-title":"J Cardiac Fail"},{"key":"10.1007\/s12350-018-1307-7_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1007\/s12350-018-1307-7_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-1307-7_bib14","unstructured":"Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis. December 12, 2017. https:\/\/www.drugs.com\/nda\/patisiran_171116.html. Accessed 2 Apr 2018."},{"key":"10.1007\/s12350-018-1307-7_bib15","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-018-1307-7_bib16","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-018-1307-7_bib17","unstructured":"U.S. Preventive Services Task Force Procedure Manual. Rockville, MD: U.S. Preventive Services Task Force; 2015."},{"key":"10.1007\/s12350-018-1307-7_bib18","unstructured":"Committee to assess health risks from exposure to low levels of ionizing radiation, Nuclear Radiation Studies Board, Division on Earth Life Studies, National Research Council of the National Academies. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington: The National Academies Press; 2006."},{"key":"10.1007\/s12350-018-1307-7_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1088\/0952-4746\/32\/3\/205","article-title":"RadRAT: a radiation risk assessment tool for lifetime cancer risk projection","volume":"32","author":"De Gonzalez","year":"2012","journal-title":"J Radiol Prot"},{"key":"10.1007\/s12350-018-1307-7_bib20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.107.688101","article-title":"Radiation dose to patients from cardiac diagnostic imaging","volume":"116","author":"Einstein","year":"2007","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-1307-7_bib21","first-page":"1117","article-title":"Radiation absorbed dose from 99mTc-labeled bone imaging agents. Task Group of the Medical Internal Radiation Dose Committee, The Society of Nuclear Medicine","volume":"30","author":"Weber","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-018-1307-7_bib22","unstructured":"Kit for the preparation of 99mTc-pyrophosphate injection for diagnostic use, Rx only. March 2008. http:\/\/www.pharmalucence.com\/images\/PyrophosphateInsert.pdf. Accessed 2 Apr 2018."},{"key":"10.1007\/s12350-018-1307-7_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0146645314558019","article-title":"Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. ICRP Publication 128","volume":"44","author":"Mattsson","year":"2015","journal-title":"Ann ICRP"},{"key":"10.1007\/s12350-018-1307-7_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of (99 m)Tc-pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-018-1307-7_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1667\/RR0763.1","article-title":"Solid cancer incidence in atomic bomb survivors: 1958-1998","volume":"168","author":"Preston","year":"2007","journal-title":"Radiat Res"},{"key":"10.1007\/s12350-018-1307-7_bib26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s12350-018-1307-7_bib27","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s12350-018-1307-7_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1007\/s12350-018-1307-7_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1007\/s12350-018-1307-7_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-caribbean heart failure in the United Kingdom: Cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1007\/s12350-018-1307-7_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Upsala J Med Sci"},{"key":"10.1007\/s12350-018-1307-7_bib32","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"10.1007\/s12350-018-1307-7_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","article-title":"Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: Can we identify affected patients earlier?","volume":"24","author":"Rubin","year":"2017","journal-title":"Amyloid"},{"key":"10.1007\/s12350-018-1307-7_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.298.3.317","article-title":"Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography","volume":"298","author":"Einstein","year":"2007","journal-title":"JAMA"},{"key":"10.1007\/s12350-018-1307-7_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1148\/radiol.11102452","article-title":"Impact of reduced patient life expectancy on potential cancer risks from radiologic imaging","volume":"261","author":"Brenner","year":"2011","journal-title":"Radiology"},{"key":"10.1007\/s12350-018-1307-7_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1007\/s12350-018-1307-7_bib37","unstructured":"Dorbala S, Bokhari S, Miller E, Bullock-Palmer R, Soman P, Thompson R. ASNC practice points: 99m-technetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. https:\/\/www.asnc.org\/Files\/Practice%20Resources\/Practice%20Points\/ASNC%20Practice%20Point-99mTechnetiumPyrophosphateImaging2016.pdf. 2016. Accessed 2 Apr 2018."},{"key":"10.1007\/s12350-018-1307-7_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","article-title":"Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-018-1307-7_bib39","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-1307-7_bib40","unstructured":"Mattsson S. SV: DPD dosimetry. personal communications: Email to Andrew J. Einstein, February 13, 2018."},{"key":"10.1007\/s12350-018-1307-7_bib41","unstructured":"Summary of Product Characteristics for Teceos, kit for radiopharmaceutical preparation. January 2017. https:\/\/curiumpharma.com\/wp-content\/uploads\/2017\/04\/T1900nJ.pdf. Accessed 2 Apr 2018."},{"key":"10.1007\/s12350-018-1307-7_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jacc.2013.10.092","article-title":"Patient-centered imaging: shared decision making for cardiac imaging procedures with exposure to ionizing radiation","volume":"63","author":"Einstein","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-018-1307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12350-018-1307-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123017476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123017476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-018-1307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:07:27Z","timestamp":1761026847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123017476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1071358123017476"],"URL":"https:\/\/doi.org\/10.1007\/s12350-018-1307-7","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-018-1307-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}